Trial data reveals that children with Type 1 diabetes using a hybrid closed-loop system and their parents do not report an increase in diabetes-related burden than those using a sensor-augmented insulin pump.
Erin C Cobry, an assistant professor of paediatrics at the Barbara Davis Center for Childhood Diabetes, University of Colorado Anschutz Medical Campus, and colleagues found no significant differences in hypoglycaemia fear, diabetes-related stress and other self-reported outcomes for trial participants using a t:slim X2 insulin pump with Control-IQ technology (Tandem Diabetes Care) compared with participants using their own insulin pump or a provided t:slim X2 insulin pump with predictive low-glucose suspend feature.
“Advancements in diabetes therapies offer ways to improve diabetes outcomes and reduce long-term complications; however, these advancements cannot come at the expense of the quality of life of the child and family,” Cobry told specialty clinical information website Healio. “Therefore, it is very important that ease of use and quality of life are part of the evaluation of novel therapies for type 1 diabetes. The results of this study indicate that hybrid closed-loop systems can successfully be used for glycaemic improvement without creating increased burden on children with type 1 diabetes or their parents.”
